Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
VANSIL (oxamniquine) is an oral small-molecule anthelmintic approved in 1980 for treatment of schistosomiasis, a parasitic infection affecting millions in endemic regions. The drug targets Schistosoma mansoni through a mechanism that disrupts the parasite's ability to survive in host tissue. It represents a legacy therapeutic in tropical medicine with significant public health impact in developing markets.
Mature product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting a smaller, stable brand team focused on profitability rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
VANSIL represents a specialized tropical medicine career path with limited growth trajectory but stable market presence in developing regions. Professionals joining this team would focus on market access, regulatory navigation in endemic countries, and public health partnerships rather than commercial scaling.
Worked on VANSIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.